Since I am mostly out of pocket this week — we will wait to detail the Amazon spend until around the middle of the following week.

And as you can see, Lilly tends to spend less than the other majors, concentrating its efforts on the preserving and defending its blockbuster weight-loss franchises:

…Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs….

Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the “Inflation Reduction Act” (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)….

Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the “Inflation Reduction Act” (HR.5376); CMS National Coverage Determination on Alzheimer’s disease; One Big Beautiful Bill Act (HR.1)….

Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality….

Pharmaceutical intellectual property issues….

Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)….

Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act….

Snow… now, all shoveled, but it is still drifting down in big wheeling flakes, here… almost lazily. Heh.

नमस्ते